Decipher Test Clinically Validated as a Predictor of Overall Survival in Men with Prostate Cancer
Decipher Test Clinically Validated as a Predictor of Overall Survival in Men with Prostate Cancer Decipher test validated in study of the practice-changing Phase 3 RTOG 96-01 clinical trial News provided by Share this article Share this article SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers, today announced publication of the results, in JAMA Oncology, from an analysis of the NRG Oncology Phase 3 randomized controlled tr...
Source: prnewswire.com